SciSparc Ltd., a clinical-stage pharmaceutical company, announced the successful dosing of the first patient in its SCI-210 clinical trial for Autism Spectrum Disorder (ASD) on March 14, 2024. The trial is being conducted at the Soroka Medical Center and targets pediatric patients. This marks a significant advancement following the company's recent update on the delivery of its SCI-210 treatment to the clinical site. The treatment comprises a combination of cannabidiol-rich oil and CannAmide, SciSparc's proprietary palmitoylethanolamide-based tablets. The study is designed as a randomized, double-blind, placebo-controlled trial with cross-over, set to last 20 weeks and enroll 60 children. It aims to assess the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. The primary efficacy...Show More

SciSparc Ltd., a clinical-stage pharmaceutical company, announced the successful dosing of the first patient in its SCI-210 clinical trial for Autism Spectrum Disorder (ASD) on March 14, 2024. The trial is being conducted at the Soroka Medical Center and targets pediatric patients. This marks a significant advancement following the company's recent update on the delivery of its SCI-210 treatment to the clinical site. The treatment comprises a combination of cannabidiol-rich oil and CannAmide, SciSparc's proprietary palmitoylethanolamide-based tablets. The study is designed as a randomized, double-blind, placebo-controlled trial with cross-over, set to last 20 weeks and enroll 60 children. It aims to assess the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. The primary efficacy endpoints include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement scale, and determining the effective therapeutic dosage. SciSparc specializes in cannabinoid pharmaceuticals and is also engaged in drug development programs for Tourette Syndrome, Alzheimer’s disease, pain, and status epilepticus. The company cautions that the forward-looking statements in the press release are subject to risks and uncertainties, and actual results may differ materially from those projected.